×
Ophthalmic manifestations of coronavirus disease 2019 and ocular side effects of invest...
https://doi.org/10.1097/ICU.0000000000000682
Current Opinion in Ophthalmology; Olson DJ, Ghosh A et. al.

Aug 2nd, 2020 - To compile and report the ocular manifestations of coronavirus disease 2019 (COVID-19) infection and summarize the ocular side effects of investigational treatments of this disease. Conjunctivitis is by far the most common ocular manifestation of COVID-19 with viral particles being isolated from tears/secretions of infected individuals. Multiple therapeutic options are being explored across a v...

COVID-19 associated coagulopathy and inflammatory response: what do we know already and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389937
Anesthesia and Analgesia; Görlinger K, Dirkmann D et. al.

Aug 2nd, 2020 - Patients with COVID-19 frequently experience a coagulopathy associated with a high incidence of thrombotic events leading to poor outcomes. Here, biomarkers of coagulation (such as D-dimer, fibrinogen, platelet count), inflammation (such as interleukin-6) and immunity (such as lymphocyte count) as well as clinical scoring systems (such as SOFA, ISTH DIC and SIC score) can be helpful in predicti...

Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations f...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365054
Journal of Geriatric Oncology; Battisti NML, Mislang AR et. al.

Jul 27th, 2020 - The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group including geriatric assessment (GA), surgery, radiotherapy, systemic treatment, palliat...

Crosstalk between COVID-19 and prostate cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378980
Prostate Cancer and Prostatic Diseases; Bahmad HF, Abou-Kheir W

Jul 27th, 2020 - A new coronavirus, named SARS-CoV-2, emerged in Wuhan city, China, in December 2019 causing atypical pneumonia and affecting multiple body organs. The rapidly increasing numbers of infected patients and deaths due to COVID-19 disease necessitated declaring it as a global pandemic. Efforts were combined since then to rapidly develop a treatment and/or a vaccine to combat the deadly virus. Drug r...

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362818
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy; Drożdżal S, Rosik J et. al.

Jul 27th, 2020 - In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloro...

Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intraveno...
https://doi.org/10.12659/AJCR.925521
The American Journal of Case Reports; Waqas Khan HM, Parikh N et. al.

Jul 24th, 2020 - BACKGROUND Coronavirus disease 2019 (COVID-19) continues to spread, with confirmed cases now in more than 200 countries. Thus far there are no proven therapeutic options to treat COVID-19. We report a case of COVID-19 with acute respiratory distress syndrome who was treated with high-dose vitamin C infusion and was the first case to have early recovery from the disease at our institute. CASE RE...

Highlighting the role of veterinary pharmacists in zoonotic diseases including COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330589
Journal of the American Pharmacists Association : JAPhA; Stafford EG

Jul 24th, 2020 - To highlight veterinary pharmacy as a career path for pharmacists as well as to describe the unique contribution of veterinary pharmacists during zoonotic disease outbreaks. Veterinary pharmacy is an often unknown and therefore, underrepresented career path for pharmacists. Uniquely, pharmacists-even untrained in veterinary medicine-are the only health professionals legally allowed to provide c...

Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404409
Journal of Medical Virology; van Gerwen M, Alsen M et. al.

Jul 24th, 2020 - Coronavirus disease 2019 (COVID-19) is a global pandemic and information on risk factors for worse prognosis is needed to accurately identify patients at risk and potentially provide insight into therapeutic options. In this retrospective cohort study, including 3703 patients with laboratory confirmed COVID-19, we identified risk factors associated with all-cause mortality, need for hospitaliza...

The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373339
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology; Machhi J, Herskovitz J et. al.

Jul 22nd, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19). SARS-CoV-2, is a positive-sense single-stranded RNA virus with epithelial cell and respiratory system proclivity. Like its predecessor, SARS-CoV, COVID-19 can lead to life-threatening disease. Due to wide geographic impact affecting an extremely high proportion of the wo...

Cytokine storm syndrome in coronavirus disease 2019: A narrative review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404514
Journal of Internal Medicine References; Gao YM, Xu G et. al.

Jul 22nd, 2020 - Cytokine storm syndrome (CSS) is a critical clinical condition induced by a cascade of cytokine activation, characterized by overwhelming systemic inflammation, hyperferritinaemia, haemodynamic instability and multiple organ failure (MOF). At the end of 2019, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and rapidly developed into a ...

Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
https://doi.org/10.1128/JVI.00985-20
Journal of Virology; Vanderheiden A, Ralfs P et. al.

Jul 21st, 2020 - The newly emerged human coronavirus, SARS-CoV-2, has caused a pandemic of respiratory illness. Current evidence suggests that severe cases of SARS-CoV-2 are associated with a dysregulated immune response. However, little is known about how the innate immune system responds to SARS-CoV-2. Here, we modeled SARS-CoV-2 infection using primary human airway epithelial (pHAE) cultures, which are maint...

Inhibiting Fusion with Cellular Membrane System: Therapeutic Options to Prevent Severe ...
https://doi.org/10.1152/ajpcell.00260.2020
American Journal of Physiology. Cell Physiology; Mitra P

Jul 20th, 2020 - Severe acute respiratory syndrome coronavirus (SARS-CoV), an enveloped virus with a positive-sense single-stranded RNA genome facilitates the host cell entry through intricate interactions with proteins and lipids of the cell membrane. The detailed molecular mechanism involves binding to the host cell receptor and fusion at the plasma membrane or after being trafficked to late endosomes under f...

ACE2 gene variants may underlie interindividual variability and susceptibility to COVID...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366459
European Journal of Human Genetics : EJHG; Benetti E, Tita R et. al.

Jul 18th, 2020 - In December 2019, an initial cluster of interstitial bilateral pneumonia emerged in Wuhan, China. A human-to-human transmission was assumed and a previously unrecognized entity, termed coronavirus disease-19 (COVID-19) due to a novel coronavirus (SARS-CoV-2) was described. The infection has rapidly spread out all over the world and Italy has been the first European country experiencing the ende...

COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
https://doi.org/10.1177/1073858420941476
The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry; Kempuraj D, Selvakumar GP et. al.

Jul 17th, 2020 - Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China. COVID-19 is a global public health emergency of international concern. COVID-19 causes mild to severe illness with high morbidity and mortality, especially in preexisting risk groups. Therapeutic options are now limited to COVI...

Running out of bullets: the challenging management of acute hepatitis and SARS-COV-2 fr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404864
Liver International : Official Journal of the International Association for the Study of the Liver; Colaneri M, Valsecchi P et. al.

Jul 17th, 2020 - Liver impairment is frequent in patients with novel coronavirus disease (COVID-19) and direct viral tropism for the liver has been proven. Since several of the currently administered drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are possibly hepatotoxic, the management of patients with COVID-19 and liver failure is still an almost unexplored field. Taking this chall...

Systematic review and meta-analysis of effectiveness of treatment options against SARS-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404948
Journal of Medical Virology REFERENCES; Thoguluva Chandrasekar V, Venkatesalu B et. al.

Jul 15th, 2020 - Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, v...

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critical...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351645
Critical Care (London, England); Lecronier M, Beurton A et. al.

Jul 12th, 2020 - The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients. The present report took the opportunity of compassionate use and succes...

Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351538
Journal of Racial and Ethnic Health Disparities; Sharma S, Cain J et. al.

Jul 11th, 2020 - Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has ravaged many urban and high-density areas in the USA. However, rural areas (despite their low population density) may be especially vulnerable to poor outcomes from COVID-19, owing to limited healthcare infrastructure, long distances to advanced health care, and population c...

Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330277
Epidemiology and Infection; Enzmann MO, Erickson MP et. al.

Jul 1st, 2020 - The majority of available US-published reports present populations with community spread in urban areas. The objective of this report is to describe a rural healthcare system's utilisation of therapeutic options available to treat Coronavirus Disease 2019 (COVID-19) and subsequent patient outcomes. A total of 150 patients were treated for COVID-19 at three hospitals in the Dakotas from 21 March...

Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337665
Journal of Crohn's & Colitis; Noor NM, Hart AL et. al.

Jun 30th, 2020 - There have been immediate and profound impacts of SARS-CoV-2 and COVID-19 on healthcare services worldwide with major consequences for non-COVID-19 related healthcare. Alongside efforts to reconfigure services and enable continued delivery of safe clinical care for patients with IBD, consideration must also be given to management of IBD research activity. In many centres there has been an effec...